BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yoo JJ, Chung GE, Lee JH, Nam JY, Chang Y, Lee JM, Lee DH, Kim HY, Cho EJ, Yu SJ, Kim YJ, Yoon JH; Seoul Liver Group. Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. Cancer Res Treat 2018;50:366-73. [PMID: 28521494 DOI: 10.4143/crt.2017.126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Marasco G, Poggioli F, Colecchia A, Cabibbo G, Pelizzaro F, Giannini EG, Marinelli S, Rapaccini GL, Caturelli E, Di Marco M, Biasini E, Marra F, Morisco F, Foschi FG, Zoli M, Gasbarrini A, Svegliati Baroni G, Masotto A, Sacco R, Raimondo G, Azzaroli F, Mega A, Vidili G, Brunetto MR, Nardone G, Alemanni LV, Dajti E, Ravaioli F, Festi D, Trevisani F, Italian Liver Cancer Ita Li Ca Group OBOT. A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. Cancers (Basel) 2021;13:2677. [PMID: 34072309 DOI: 10.3390/cancers13112677] [Reference Citation Analysis]
2 Li L, Li X, Li W, Ding X, Zhang Y, Chen J, Li W. Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal. BMC Cancer 2022;22:750. [PMID: 35810271 DOI: 10.1186/s12885-022-09841-5] [Reference Citation Analysis]
3 Xin Y, Yang Y, Liu N, Chen Y, Wang Y, Zhang X, Li X, Zhou X. Prognostic significance of systemic immune-inflammation index-based nomogram for early stage hepatocellular carcinoma after radiofrequency ablation. J Gastrointest Oncol 2021;12:735-50. [PMID: 34012662 DOI: 10.21037/jgo-20-342] [Reference Citation Analysis]
4 Kim YJ, Jung J, Joo JH, Kim SY, Kim JH, Lim YS, Lee HC, Kim JH, Yoon SM. Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C. Radiother Oncol 2019;141:95-100. [PMID: 31506181 DOI: 10.1016/j.radonc.2019.08.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
5 Jin C, Li R, Deng T, Li J, Yang Y, Li H, Chen K, Xiong H, Chen G, Wang Y. Identification and Validation of a Prognostic Prediction Model of m6A Regulator-Related LncRNAs in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:784553. [PMID: 34988119 DOI: 10.3389/fmolb.2021.784553] [Reference Citation Analysis]
6 Cho YY, Yu SJ, Lee HW, Kim DY, Kang W, Paik YH, Sung PS, Bae SH, Park SC, Doh YS, Kim KM, Jang ES, Kim IH, Kim W, Kim YJ. Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. J Hepatocell Carcinoma 2021;8:613-23. [PMID: 34169044 DOI: 10.2147/JHC.S304439] [Reference Citation Analysis]
7 Zhang T, Liu Z, Zhao X, Mao Z, Bai L. A novel prognostic score model based on combining systemic and hepatic inflammation markers in the prognosis of HBV-associated hepatocellular carcinoma patients. Artif Cells Nanomed Biotechnol 2019;47:2246-55. [PMID: 31169437 DOI: 10.1080/21691401.2019.1573174] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
8 Zhu P, Ren Q, He N, Zhou C, Jin Q, Gong Z. Construction and validation of an N6-methyladenosine-associated prognostic signature in hepatocellular carcinoma. Oncol Lett 2021;21:221. [PMID: 33613710 DOI: 10.3892/ol.2021.12482] [Reference Citation Analysis]
9 Labeur TA, Berhane S, Edeline J, Blanc JF, Bettinger D, Meyer T, Van Vugt JLA, Ten Cate DWG, De Man RA, Eskens FALM, Cucchetti A, Bonnett LJ, Van Delden OM, Klümpen HJ, Takkenberg RB, Johnson PJ. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. Liver Int 2020;40:215-28. [PMID: 31579990 DOI: 10.1111/liv.14270] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
10 Kim BH, Park JW. Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation. J Korean Med Sci 2018;33:e286. [PMID: 30402051 DOI: 10.3346/jkms.2018.33.e286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]